title: The pharmacy director's view of the implications of dose escalation.
authors.affiliation: Harvard Pilgrim Health Care, Wellesley, Massachusetts 02481-9181, USA. jim.kenney@hphc.org
authors.forename: James T
authors.initials: JT
authors.lastname: Kenney
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000191:economics; D002017:Budgets; D004305:Dose-Response Relationship, Drug; D016527:Drug Costs; D005569:Formularies as Topic; D006801:Humans; D000069285:Infliximab; D008329:Managed Care Programs / Q000191:economics / Q000458:organization & administration; D010595:Pharmacists; D014481:United States
chemical_list: D000911:Antibodies, Monoclonal; D000069285:Infliximab